These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23582282)

  • 1. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
    Tsao AS; Papadimitrakopoulou V
    Clin Lung Cancer; 2013 Jul; 14(4):311-21. PubMed ID: 23582282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
    N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
    Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
    Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
    Amler LC; Goddard AD; Hillan KJ
    Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
    Heigener DF; Reck M
    Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
    Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
    Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for epidermal growth factor receptor mutations in lung cancer.
    Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
    N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
    Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J
    Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.